Table I.
Baseline patient demographics and clinical characteristics
| Ustekinumab (n = 166) | Ixekizumab (n = 136) | |
|---|---|---|
| Age, years, mean (SD) | 44.0 (13.3) | 42.7 (12.7) |
| Sex, male, n (%) | 112 (67.5) | 90 (66.2) |
| Race, white, n (%) | 157 (95.7) | 125 (93.3) |
| Weight, kg, mean (SD) | 89.4 (24.8) | 85.8 (20.3) |
| Weight, >100.0 kg, n (%) | 45 (27.1) | 31 (23.0) |
| BMI, kg/m2, mean (SD) | 29.7 (7.0) | 28.8 (5.6) |
| PASI score, mean (SD) | 19.8 (9.0) | 19.9 (8.2) |
| PtGA score, mean (SD) | 4.0 (0.9) | 4.1 (1.0) |
| sPGA score, mean (SD) | 3.6 (0.6) | 3.6 (0.7) |
| % BSA, mean (SD) | 27.5 (16.7) | 26.7 (16.5) |
| Duration of psoriasis (years), mean (SD) | 18.2 (12.0) | 18.0 (11.1) |
| Itch NRS, mean (SD) | 6.2 (2.6) | 6.3 (2.7) |
| DLQI score, mean (SD) | 12.0 (7.3) | 11.1 (7.2) |
| Skin pain VAS, mean (SD) | 39.4 (30.8) | 42.9 (33.3) |
| 36-item Short-Form Health survey | ||
| MCS, mean (SD) | 46.5 (11.9) | 47.1 (11.5) |
| PCS, mean (SD) | 48.4 (9.8) | 47.3 (9.5) |
| European Quality of Life – 5 Dimensions | ||
| UK, mean (SD) | 0.7 (0.2) | 0.7 (0.2) |
| PsO, mean (SD) | 0.7 (0.2) | 0.7 (0.2) |
| VAS, mean (SD) | 67.4 (22.4) | 66.3 (22.2) |
| WPAI:PsO | ||
| Absenteeism, mean (SD) | 4.3 (14.9) | 3.1 (10.7) |
| Presenteeism, mean (SD) | 21.7 (29.1) | 22.1 (28.4) |
| Work Impairment, mean (SD) | 22.8 (30.1) | 23.8 (29.8) |
| Activity Impairment, mean (SD) | 29.8 (28.4) | 28.2 (30.6) |
SD: standard deviation; BMI: body mass index; PASI: Psoriasis Area and Severity Index; PtGA: patient global assessments; sPGA: static Physician’s Global Assessment; BSA: body surface area; NRS: numerical rating scale; DLQI: Dermatology Life Quality Index; VAS: visual analogue scale; MCS: mental health component score; PCS: physical health component score; PsO: psoriasis; WPAI:PsO: Work Productivity and Activity Impairment Questionnaire for Psoriasis.